Zhang Tongyi, Zhu Liyong, Cai Jianhua, He Jiaqi
Department of General Surgery, Huadong Hospital Affiliated to Fudan University, Jing'an District, 200040, Shanghai, China.
Department of General Surgery, Huadong Hospital Affiliated to Fudan University, No. 221 Yan'an West Road, Jing'an District, 200040, Shanghai, China.
Open Med (Wars). 2022 Mar 4;17(1):427-440. doi: 10.1515/med-2022-0433. eCollection 2022.
We aimed to screen the drug metabolism-related subgroups of pancreatic adenocarcinoma (PAAD) and to study the prognosis, clinical features, immune infiltration, and gene mutation differences of different subtypes in PAAD patients. All 181 cases of PAAD samples and clinical characteristics data were downloaded from The Cancer Genome Atlas (TCGA). After matching the drug metabolism-related genes downloaded from PMID 33202946 with the TCGA dataset, the drug metabolism-related genes were initially obtained. Besides, univariate Cox regression analysis was used to screen the drug metabolism genes related to the prognosis of PAAD. Moreover, the construction of the protein-protein interaction (PPI) network and gene ontology were performed. The four subgroups of PAAD obtained from unsupervised clustering analysis were systematically analyzed, including prognostic, GSVA, immune infiltration, and gene mutation analysis. A total of 83 drug metabolism genes related to the prognosis of PAAD were obtained and enriched in 16 pathways. The PPI network was composed of 248 relationship pairs. Four subgroups that can identify different subtypes of PPAD were obtained, and there were significant differences in survival and clinical characteristics, mutation types, and immune infiltration abundance between subgroups. A total of 17 different pathways among the four subgroups involved in cell cycle, response to stimulants such as drugs, and transmembrane transport. In this study, the four subgroups related to the drug metabolism of PAAD were comprehensively analyzed, and the important role of drug metabolism-related genes in the immune infiltration and prognosis of PAAD were emphasized.
我们旨在筛选胰腺腺癌(PAAD)的药物代谢相关亚组,并研究PAAD患者不同亚型的预后、临床特征、免疫浸润和基因突变差异。从癌症基因组图谱(TCGA)下载了181例PAAD样本及临床特征数据。将从PMID 33202946下载的药物代谢相关基因与TCGA数据集匹配后,初步获得了药物代谢相关基因。此外,采用单因素Cox回归分析筛选与PAAD预后相关的药物代谢基因。此外,还构建了蛋白质-蛋白质相互作用(PPI)网络并进行了基因本体分析。对通过无监督聚类分析得到的PAAD四个亚组进行了系统分析,包括预后、基因集变异分析(GSVA)、免疫浸润和基因突变分析。共获得83个与PAAD预后相关的药物代谢基因,并富集于16条通路。PPI网络由248个关系对组成。获得了四个可识别PPAD不同亚型的亚组,各亚组在生存、临床特征、突变类型和免疫浸润丰度方面存在显著差异。四个亚组中共有17条不同的通路参与细胞周期、对药物等刺激的反应以及跨膜运输。在本研究中,对PAAD的四个药物代谢相关亚组进行了综合分析,并强调了药物代谢相关基因在PAAD免疫浸润和预后中的重要作用。